Consun Pharmaceutical Group Ltd. ( (HK:1681) ) has issued an update.
Consun Pharmaceutical Group Ltd. reported a strong financial performance for the year ended December 31, 2024, with a 14.6% increase in revenue to RMB2,967,235,000 and a 16.1% rise in profit attributable to equity shareholders, amounting to RMB910,458,000. The company also announced a proposed final dividend of HKD0.3 per share, reflecting its robust earnings growth and commitment to shareholder returns.
More about Consun Pharmaceutical Group Ltd.
Consun Pharmaceutical Group Ltd. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on the production and distribution of pharmaceutical products, with a significant market presence in China.
YTD Price Performance: -15.05%
Average Trading Volume: 1,408
Technical Sentiment Signal: Sell
Current Market Cap: €893.2M
See more data about 1681 stock on TipRanks’ Stock Analysis page.